Ask the Expert: Is CBD oil safe and effective?
GREENVILLE, S.C. (WSPA)— Products containing CBD are growing in popularity and availability.
As part of our 'Ask the Expert' series, in partnership with Bon Secours St. Francis, 7NEWS spoke with a family medicine physician about CBD oil and whether it's safe and effective.
CBD oil is a product made from cannabidiol found in the cannabis plant, the same plant that produces marijuana, but doctors say it will not get you high.
'Unlike THC, which is tetrahydrocannabinol, a psychoactive compound in cannabis, CBD is non-psychoactive, meaning it does not cause a high sensation,' said Dr. Ryan Paulson.
Family medicine physician Dr. Ryan Paulson said once CBD is extracted from the cannabis plant, it is usually diluted with a carrier oil such as coconut oil or hempseed oil before being used in most commercial products.
He says doctors may recommend it for a variety of ailments.
'Common conditions where CBD oil can be recommended include chronic pain, anxiety, stress, sleep disorders, epilepsy or seizure disorders, inflammatory or autoimmune conditions such as Crohn's disease, ulcerative colitis, and skin conditions such as acne, eczema, or psoriasis,' said Dr. Ryan Paulson.
Generally, Dr. Paulson says CBD oil is safe for most people when used appropriately, but it's not recommended for everyone.
'There are definitely individuals who should not be utilizing CBD oil or should be using it with great caution… it can interact with certain medications or underlying health conditions. 'We strongly urge that we avoid use with pregnant or breastfeeding women, as there is limited research on the safety of CBD during pregnancy and breastfeeding; in children under the age of 18; people with liver issues; and those on certain medications such as warfarin, antidepressants, and benzodiazepines,' said Dr. Ryan Paulson.
Dr. Paulson says research on CBD oil is still evolving, and interactions with other treatments can vary. Therefore, consult your doctor before using these products.
'Your doctor can provide personalized guidance on proper dosage, potential interactions with other medications, and the best CBD products for your needs. That can also help you avoid any risk and ensure your overall treatment plan is effective and safe,' said Dr. Ryan Paulson.
In some cases, a doctor may prescribe CBD oil as part of their treatment plan.
'Particularly for certain medical conditions where there's strong evidence for its effectiveness,' said Dr. Ryan Paulson.
If you plan to purchase CBD oil over the counter, Dr. Paulson advises, ensure it's legitimate.
'To ensure you are purchasing a legitimate and safe CBD oil, you always want to look for third-party lab testing. Check the source and quality of the hemp and avoid brands that make unrealistic claims,' said Dr. Ryan Paulson.
To submit a health topic for our 'Ask the Expert' series, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
HERZLIYA, Israel and CALGARY, AB, June 13, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries proudly announces the third party publication of a peer-reviewed narrative review in Cureus journal titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: The article discusses the therapeutic potential of long-acting synthetic cannabidiol (CBD) in addressing chronic pain—an urgent global health challenge for which safer, more effective treatments are desperately needed. Co-authored by leading pain specialists from institutions such as Johns Hopkins University and NYU School of Medicine, the review highlights that synthetic CBD administered through extended-release formulations could offer a well-tolerated, non-opioid analgesic alternative with the potential to significantly reduce reliance on addictive opioids. Chronic pain affects over 24% of adults in the United States alone, placing a significant burden on patients, healthcare systems, and economies*. Yet, long-term treatment options remain inadequate. NSAIDs pose cumulative toxicity risks, and opioids—while effective—present serious concerns including tolerance, dependency, and overdose risk. Globally, opioid misuse results in over 100,000 deaths annually (DOI: 10.1016/ The U.S. Food and Drug Administration (FDA) has emphasized the critical need for novel, non-addictive pain therapies through its "Guidance for Industry: Non-Opioid Analgesic Development Programs". Innocan's proprietary LPT-CBD platform is uniquely positioned to align with this regulatory focus. LPT-CBD is an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by various animal studies, LPT-CBD produces steady CBD plasma levels for up to four weeks, delivers prolonged pain relief, and is well tolerated, offering a promising alternative to current opioid medication and abuse. Innocan has initiated regulatory submissions in support of advancing LPT-CBD into human clinical trials. This progress marks a pivotal step toward realizing a first-in-class, non-opioid analgesic therapy tailored for the complexities of chronic pain management. "This publication underscores the urgent need for innovative, non-opioid analgesics that offer long-lasting efficacy," said Dr. Paul J. Christo, Associate Professor and Chief of the Division of Pain Medicine at the Johns Hopkins University School of Medicine and co-author of the article. "Liposomal synthetic CBD could offer a safe and scalable solution for a variety of painful conditions." "Given the current addiction crisis, there is an immediate need to replace opioids with safer, effective alternatives," noted Dr. Eugene Vortsman, Clinical Director of Addiction Medicine and Disease Management at Northwell Health and co-author of the article. "Long-acting synthetic CBD has real potential to shift the paradigm." Iris Bincovich, Chief Executive Officer of Innocan added: "We are thrilled by this breakthrough publication. Innocan is fully committed to advancing LPT-CBD toward clinical development, with the goal of delivering an innovative and safe non-opioid analgesic solution for chronic pain management." Reference Opioid crisis: addiction, overprescription, and insufficient primary prevention, The Lancet Regional Health – Americas 2023;23: 100557. DOI: 10.1016/ Paul J. Christo, Eugene Vortsman, Christopher Gharibo, Jo Ann K. LeQuang, Joseph V. Pergolizzi. Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review. Cureus Journal of Medical Science. DOI: 10.7759/cureus.81577 * Sources: CDC, U.S. Senate Joint Economic Committee, The Lancet About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation:Iris Bincovich, CEO+1 5162104025+972-54-3012842+442037699377info@ NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo - View original content: SOURCE Innocan Pharma Corporation View original content: Sign in to access your portfolio
Yahoo
21 hours ago
- Yahoo
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
The First Trust Health Care AlphaDEX ETF (FXH) made its debut on 05/08/2007, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. For a long time now, the ETF industry has been flooded with products based on market capitalization weighted indexes, which are designed to represent the broader market or a particular market segment. Market cap weighted indexes work great for investors who believe in market efficiency. They provide a low-cost, convenient and transparent way of replicating market returns. However, some investors believe in the possibility of beating the market through exceptional stock selection, and choose a different type of fund that tracks non-cap weighted strategies: smart beta. Based on specific fundamental characteristics, or a combination of such, these indexes attempt to pick stocks that have a better chance of risk-return performance. Even though this space provides many choices to investors--think one of the simplest methodologies like equal-weighting and more complicated ones like fundamental and volatility/momentum based weighting--not all have been able to deliver first-rate results. Because the fund has amassed over $916.26 million, this makes it one of the larger ETFs in the Health Care ETFs. FXH is managed by First Trust Advisors. Before fees and expenses, FXH seeks to match the performance of the StrataQuant Health Care Index. The StrataQuant Health Care Index employs the AlphaDEX stock selection methodology to select stocks from the Russell 1000 Index. Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive cousins if all other fundamentals are the same. With on par with most peer products in the space, this ETF has annual operating expenses of 0.60%. It's 12-month trailing dividend yield comes in at 0.38%. It is important to delve into an ETF's holdings before investing despite the many upsides to these kinds of funds like diversified exposure, which minimizes single stock risk. And, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation in the Healthcare sector - about 100% of the portfolio. When you look at individual holdings, Tenet Healthcare Corporation (THC) accounts for about 2.51% of the fund's total assets, followed by Cardinal Health, Inc. (CAH) and Penumbra, Inc. (PEN). FXH's top 10 holdings account for about 23.4% of its total assets under management. The ETF has lost about -1.12% so far this year and is down about -2.11% in the last one year (as of 06/13/2025). In the past 52-week period, it has traded between $93.63 and $113.83. FXH has a beta of 0.75 and standard deviation of 16.10% for the trailing three-year period, which makes the fund a medium risk choice in the space. With about 77 holdings, it effectively diversifies company-specific risk. First Trust Health Care AlphaDEX ETF is a reasonable option for investors seeking to outperform the Health Care ETFs segment of the market. However, there are other ETFs in the space which investors could consider. Vanguard Health Care ETF (VHT) tracks MSCI US Investable Market Health Care 25/50 Index and the Health Care Select Sector SPDR ETF (XLV) tracks Health Care Select Sector Index. Vanguard Health Care ETF has $15.50 billion in assets, Health Care Select Sector SPDR ETF has $35.07 billion. VHT has an expense ratio of 0.09% and XLV charges 0.08%. Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Health Care ETFs. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report First Trust Health Care AlphaDEX ETF (FXH): ETF Research Reports Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report Health Care Select Sector SPDR ETF (XLV): ETF Research Reports Vanguard Health Care ETF (VHT): ETF Research Reports Penumbra, Inc. (PEN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 hours ago
- Yahoo
Exhale Wellness Launches Its THCa Flower 2025 Lineup
LOS ANGELES, June 13, 2025 /PRNewswire/ -- Exhale Wellness, a leading name in the U.S. hemp-based wellness market, has officially launched its highly anticipated THCa flower strains for 2025. The lineup includes standout products like Purple Gelato and Lemon Cherry Gelato, already earning recognition for their premium quality, wellness potential, verified lab testing, and rave customer reviews. Industry analysts believe this release has firmly positioned Exhale Wellness as a frontrunner in the THCa flower market for the year. Known for its unique ability to offer non-psychoactive benefits in its raw form and psychoactive effects when heated, THCa flower continues to gain momentum among both wellness-focused consumers and recreational users seeking an alternative to traditional THC products. Exhale's Leading THCa Strains for 2025: User Feedback and Highlights Exhale Wellness's newest THCa flower strains, Purple Gelato and Lemon Cherry Gelato, are earning praise for their rich flavor profiles, balanced effects, and verified quality. Here are a few notable highlights of these products, along with honest user feedback that reflects their growing popularity in 2025. Purple Gelato Exhale's Purple Gelato, an Indica-dominant hybrid, is quickly gaining attention for its sweet, creamy flavor layered with subtle citrus notes. Its visually striking purple buds, covered in glistening trichomes, have been reported to contain 18.4% total THCa. While new users are praising its smooth, euphoric effects and gentle body relaxation when smoked or baked, experienced consumers note its balanced impact, offering calm and mood elevation without excessive sedation. Compared to other brands, many report that Exhale's Purple Gelato delivers a more refined and consistent experience. Specifications Strain Type: Indica-dominant hybrid THCa Content: Contains 18.4% total THCa Growing Practices: US-grown and organic Legal Compliance: Federal Farm Bill compliant (>0.3% Delta-9 THC) Lab Testing: Third-party lab tested Packaging Sizes: 3.5g, 7g, 14g, and 28g Shipping Restrictions: Not available in Hawaii, Idaho, Minnesota, Oregon, Rhode Island, Utah, and Vermont Additional Features: Discreet shipping and a 30-day money-back guarantee Reviews "The flavor of Purple Gelato is truly impressive. The sweet berries combined with a creamy undertone make every puff smooth and enjoyable. It's one of the finest THCa flowers I've experienced—delicious and satisfying." —Michael Jones, Denver, CO. "Purple Gelato delivers a perfectly balanced effect that helps me unwind without feeling overly sedated. It's ideal for evenings when I want to relax but remain clear-headed and functional." — Ayesha Volter, Portland, OR. Lemon Cherry Gelato Lemon Cherry Gelato, another top Indica-dominant hybrid in Exhale's 2025 THCA flower lineup, offers a distinct taste of sweet cherries combined with tangy lemon, delivering a uniquely satisfying and refreshing experience with every inhale. The THCA content stands out at an impressive 29.1%, providing users a more powerful physical relaxation paired with an uplifting cerebral effect. Most users consider it ideal for unwinding after a long day. Visually, the flower features beautiful green and purple buds coated in a dense layer of trichomes, making it as pleasing to the eye as it is to the palate. Specifications Total THCa: A total of 29.1% Strain Type: Indica-dominant hybrid Cultivation: Organic, natural, and US-based Lab Testing: From verified third-party labs Compliance: Farm Bill compliant Available Sizes: 14g and 28g Shipping Restrictions: Not available for shipment to California, Hawaii, Idaho, Minnesota, Oregon, Rhode Island, Utah, and Vermont Additional Benefits: 30-day return guarantee and discreet shipping Reviews "The bright lemon and sweet cherry flavors make Lemon Cherry Gelato a real treat. The smooth inhale and complex aroma make it stand out. It's easily one of the best-flavored THCa flowers I've experienced, combining taste and potency perfectly." - David Carter, Austin, TX. "I find Lemon Cherry Gelato excellent for relaxing after work without feeling sleepy. The cerebral uplift helps me stay focused and creative while providing soothing physical calm. It's become my go-to strain for unwinding while staying productive." - Samantha Lee, Seattle, WA. About Exhale Wellness Exhale Wellness is a top-tier hemp-based wellness brand based in Los Angeles, US. It is recognized across the country for its high-quality, federally compliant products, made with organic, home-grown, vegan ingredients. Most of its offerings, including THCa flowers, gummies, and vapes, are verified by third-party labs. The brand boasts a nationwide customer base with over 20,000 five-star reviews. Media Contact Company Name: Exhale WellnessWebsite: Person: Exhale Wellness Support TeamE-mail: support@ Number: (323) 448-3810Address: Charlotte, NC 28273Country: United States View original content: SOURCE Exhale Wellness Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
